Atlas Trials

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Clinical trial NCT06423170 · RECRUITING

Trial details

NCT number
NCT06423170
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Gallbladder Cancer
Start date
2023-06-01
Primary completion
2025-12-31
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.